Leukemia News

The FDA granted fast track designation to mocravimod in combination with allogeneic hematopoietic stem cell transplantation for post-remission therapy of acute myeloid leukemia.

The FDA approved ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia.

Treatment with a hypomethylating agent may activate or upregulate SALL4, an oncogene that plays a key role in myelodysplastic syndrome and other cancers, according to study results published in The New England Journal of Medicine.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

ASCO and the Association of Community Cancer Centers have jointly developed recommendations for improving equity, diversity and inclusion in cancer clinical trials.

The FDA approved azacitidine for treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.

Most patients with cancer demonstrated antibody responses to COVID-19 vaccination after two doses of the mRNA-1273 vaccine, according to an observational study published in JAMA Oncology.

The FDA placed a partial clinical hold on a phase 1 dose-escalation study of a therapy under investigation for certain patients with blood cancer.

One of the major complaints of clinicians who treat patients with chimeric antigen receptor T-cell therapies is the time required to produce the highly individualized treatment.

Survivors of adolescent and young-adult acute myeloid leukemia and acute lymphoblastic leukemia had lower long-term survival rates than the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.